Literature DB >> 10524452

Costs, charges, and reimbursements for persons with sickle cell disease.

P J Nietert1, M R Abboud, J S Zoller, M D Silverstein.   

Abstract

PURPOSE: The aims of this study were to describe health care costs and charges for patients with sickle cell disease (SCD) and identify predictors of high use. PATIENTS AND METHODS: Patients with SCD were identified by International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) codes from a university hospital's administrative databases from January 1, 1996, to September 30, 1997. Clinical and administrative data were gathered on each patient for all hospital admissions and ambulatory clinic visits. Logistic regression models were used to determine predictors of high health care use.
RESULTS: A total of 947 patients with SCD were identified, 73% of whom resided within three South Carolina counties. On average, there were 0.9 admissions per patient per year and 8.0 outpatient visits per patient per year. Mean inpatient hospital charges, physician charges, and direct hospital costs per admission were $7290, $1589, and $5405, respectively, and the average length of stay was 4.5 days. Mean hospital charges, physician charges, and direct hospital costs per outpatient visit were $305, $169, and $688, respectively. Forty percent of the inpatient hospital charges were accounted for by only 4.2% of the patients. Residing in a distant county and being admitted with a diagnosis of painful respiration were found to be predictors of excessive charges and expenses beyond expected reimbursements.
CONCLUSIONS: Patients with SCD are frequent users of health care services. Charges and costs are distributed disproportionately across these patients. Predictors of excessive hospital charges include living geographically distant from the hospital and being admitted with a diagnosis of painful respiration.

Entities:  

Mesh:

Year:  1999        PMID: 10524452     DOI: 10.1097/00043426-199909000-00010

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  10 in total

1.  Sickle-cell disease in California: a population-based description of emergency department utilization.

Authors:  Julie A Wolfson; Sheree M Schrager; Thomas D Coates; Michele D Kipke
Journal:  Pediatr Blood Cancer       Date:  2010-11-24       Impact factor: 3.167

2.  Sickle cell disease in California: sociodemographic predictors of emergency department utilization.

Authors:  Julie A Wolfson; Sheree M Schrager; Rachna Khanna; Thomas D Coates; Michele D Kipke
Journal:  Pediatr Blood Cancer       Date:  2011-02-25       Impact factor: 3.167

3.  A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010/11.

Authors:  E Pizzo; A A Laverty; K J Phekoo; G AlJuburi; S A Green; D Bell; A Majeed
Journal:  J Public Health (Oxf)       Date:  2014-05-05       Impact factor: 2.341

4.  Economic burden of sickle cell disease in Brazil.

Authors:  Ana Cristina Silva-Pinto; Fernando F Costa; Sandra Fatima Menosi Gualandro; Patricia Belintani Blum Fonseca; Carmela Maggiuzzu Grindler; Homero C R Souza Filho; Carolina Tosin Bueno; Rodolfo D Cançado
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

Review 5.  Sickle cell anaemia: epidemiology and cost of illness.

Authors:  Paul J Nietert; Marc D Silverstein; Miguel R Abboud
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  Needs Assessment for Patients with Sickle Cell Disease in South Carolina, 2012.

Authors:  Alyssa M Schlenz; Andrea D Boan; Daniel T Lackland; Robert J Adams; Julie Kanter
Journal:  Public Health Rep       Date:  2016 Jan-Feb       Impact factor: 2.792

7.  Emergency Department (ED), ED Observation, Day Hospital, and Hospital Admissions for Adults with Sickle Cell Disease.

Authors:  David M Cline; Susan Silva; Caroline E Freiermuth; Victoria Thornton; Paula Tanabe
Journal:  West J Emerg Med       Date:  2018-02-12

8.  Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents.

Authors:  Paavani S Reddy; Stephanie W Cai; Leonardo Barrera; Kathryn King; Sherif M Badawy
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

9.  Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program.

Authors:  Kerri A Nottage; Jane S Hankins; Matthew Smeltzer; Fawaz Mzayek; Winfred C Wang; Banu Aygun; James G Gurney
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

10.  Association between Participants' Characteristics, Patient-Reported Outcomes, and Clinical Outcomes in Youth with Sickle Cell Disease.

Authors:  Sherif M Badawy; Leonardo Barrera; Stephanie Cai; Alexis A Thompson
Journal:  Biomed Res Int       Date:  2018-07-18       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.